These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28673393)

  • 21. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
    Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.
    Piris-Villaespesa M; Alvarez-Twose I
    Front Pharmacol; 2020; 11():443. PubMed ID: 32346366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A; Cross NC
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib].
    Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA
    Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
    Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
    Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic mastocytosis: current classification and novel therapeutic options.
    Barbie DA; Deangelo DJ
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mastocytosis: revisited with new cytogenetic data].
    Vaes M; Vereecken P; de Wind R; Andry G; Li R; Bron D
    Rev Med Brux; 2012; 33(1):12-21. PubMed ID: 22512145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
    Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
    N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
    Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
    N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel approaches in the treatment of systemic mastocytosis.
    Quintas-Cardama A; Aribi A; Cortes J; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2006 Oct; 107(7):1429-39. PubMed ID: 16948123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.
    Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G
    J Clin Oncol; 2006 Feb; 24(4):e6-7. PubMed ID: 16446324
    [No Abstract]   [Full Text] [Related]  

  • 35. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
    Bain BJ
    Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular alterations underlying eosinophilic and mast cell malignancies.
    Sadrzadeh H; Abdel-Wahab O; Fathi AT
    Discov Med; 2011 Dec; 12(67):481-93. PubMed ID: 22204765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Models of Therapy: When Acute Leukemia Becomes Chronic.
    Ustun C; Stone R; Weisdorf D
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1856-7. PubMed ID: 26183079
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.
    Tefferi A; Lasho TL; Brockman SR; Elliott MA; Dispenzieri A; Pardanani A
    Haematologica; 2004 Jul; 89(7):871-3. PubMed ID: 15257945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.